Tin tức & Cập nhật
Xem bài viết Sản phụ khoa
Xem
Chỉ hiển thị Multimedia

Fulvestrant-palbociclib combo pre-progression improves PFS in ESR1+ mBC
12 Jan 2022
bởiRoshini Claire Anthony
Switching to a fulvestrant-palbociclib regimen prior to disease progression after detection of elevated ESR1 mutations in the blood of patients with hormone receptor-positive (HR+), HER2-negative (HER2-) metastatic breast cancer (mBC) who were receiving aromatase inhibitors (AIs) plus palbociclib extended their progression-free survival (PFS), results of the phase III PADA-1 trial showed.
12 Jan 2022







